DCTH Stock - Delcath Systems, Inc.
Unlock GoAI Insights for DCTH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $37.20M | $2.06M | $2.72M | $3.56M | $1.65M |
| Gross Profit | $31.02M | $1.43M | $2.03M | $2.88M | $1.01M |
| Gross Margin | 83.4% | 69.2% | 74.8% | 81.1% | 61.1% |
| Operating Income | $-12,410,000 | $-38,182,000 | $-33,853,000 | $-24,531,000 | $-21,303,000 |
| Net Income | $-26,386,000 | $-47,678,000 | $-36,508,000 | $-25,649,000 | $-24,156,000 |
| Net Margin | -70.9% | -2308.9% | -1342.7% | -721.5% | -1467.6% |
| EPS | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Visit WebsiteEarnings History & Surprises
DCTHEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.06 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.02 | $0.02 | 0.0% | = MET |
Q3 2025 | Aug 6, 2025 | $0.03 | $0.07 | +169.2% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.10 | $0.03 | -70.0% | ✗ MISS |
Q1 2025 | Mar 6, 2025 | $-0.10 | $0.05 | +150.0% | ✓ BEAT |
Q4 2024 | Nov 8, 2024 | $-0.13 | $-0.03 | +76.9% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $-0.34 | $-0.48 | -41.2% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.43 | $-0.43 | 0.0% | = MET |
Q1 2024 | Mar 26, 2024 | $-0.67 | $-0.48 | +28.4% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.51 | $-0.61 | -19.6% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.67 | $-0.58 | +13.4% | ✓ BEAT |
Q2 2023 | May 22, 2023 | $-0.57 | $-0.77 | -35.1% | ✗ MISS |
Q1 2023 | Mar 27, 2023 | $-0.68 | $-0.86 | -26.5% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-1.05 | $-0.92 | +12.4% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.88 | $-1.18 | -34.1% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.84 | $-1.00 | -19.0% | ✗ MISS |
Q1 2022 | Mar 25, 2022 | $-0.93 | $-0.69 | +25.8% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.91 | $-0.94 | -3.3% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.98 | $-0.96 | +2.0% | ✓ BEAT |
Latest News
Frequently Asked Questions about DCTH
What is DCTH's current stock price?
What is the analyst price target for DCTH?
What sector is Delcath Systems, Inc. in?
What is DCTH's market cap?
Does DCTH pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to DCTH for comparison